As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...

GE HealthCare is raising the curtain on its spearhead into the field of photon-counting CT, the Photonova Spectra, with an ...

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences' proposed purchase of heart ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...